Involvement of glucose and ATP-sensitive potassium (K+) channels on morphine-induced conditioned place preference.
In the present study, the effects of glucose and ATP-sensitive K+ channel compounds on the acquisition of morphine-induced place preference in male mice were investigated. Subcutaneous administration of different doses of morphine (2.5-7.5 mg/kg) produced a dose-dependent conditioned place preference. With a 3-day conditioning schedule, it was found that glucose (100, 200, 500 and 1000 mg/kg), diazoxide (15, 30 and 60 mg/kg) or glibenclamide (3, 6 and 12 mg/kg) did not produce significant place preference or place aversion. Intraperitoneal administration of the glucose (1000 mg/kg) or glibenclamide (6 and 12 mg/kg) with a lower dose of morphine (0.5 mg/kg) elicited the significant conditioned place preference. The response of glibenclamide (6 mg/kg) was reversed by diazoxide (15, 30 and 60 mg/kg). Drug injections had no effects on locomotor activity during the test sessions. It is concluded that glucose and the ATP-sensitive K+ channel may play an active role in morphine reward.
Zarrindast
Mohammad R
MR
Department of Pharmacology and Iranian National Center for addiction Studies, Medical Sciences, University of Tehran, Iran. zarinmr@ams.ac.ir
Sattari-Naeini
Manochehr
M
Khalilzadeh
Azita
A
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D003981:Diazoxide / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005947:Glucose / Q000494:pharmacology*; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D054086:KATP Channels / Q000037:antagonists & inhibitors / Q000502:physiology*; D008124:Locomotion / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology; D012201:Reward; D013037:Spatial Behavior / Q000187:drug effects* / Q000502:physiology
D054086:KATP Channels; D026902:Potassium Channel Blockers; D009020:Morphine; D005947:Glucose; D003981:Diazoxide; D005905:Glyburide